THE PRESENT INVENTION RELATES TO A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SCHIZOPHRENIA AND ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDERS, COMPRISING A COMPOUND WHICH IS ACTIVE ON A TRACE AMINE-ASSOCIATED RECEPTOR 1 (TAAR1 AGONIST) AND AN ANTIPSYCHOTIC DRUG. IT HAS SURPRISINGLY BEEN FOUND THAT SUCH A COMBINATION CAN REDUCE METABOLIC SIDE EFFECTS WHICH APPEAR IF USING AN ANTIPSYCHOTIC DRUG ALONE.